A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
This study has been completed.
Sponsor:
Syndax Pharmaceuticals
Information provided by:
Syndax Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00828854
First received: January 23, 2009
Last updated: February 2, 2010
Last verified: February 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Estimated Study Completion Date: | No date given |
| Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |